查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930028

鴉片類藥物使用障礙（OUD）市場規模、佔有率、成長及全球產業分析：依藥物類別、給藥途徑、通路和地區劃分的洞察與預測（2025-2034）

Opioid Use Disorder Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 129 Pages | 商品交期: 請詢問到貨日

價格

鴉片類藥物使用障礙（OUD）市場成長驅動因素

到2025年，全球鴉片類藥物使用障礙（OUD）市場規模達到 39.2億美元，預計2026年將達到 42.6億美元，到2034年將進一步成長至 92.7億美元。市場成長的主要驅動因素包括鴉片類藥物成癮的日益普遍、政府介入計畫的擴展以及藥物輔助治療方案的日益普及。2025年，北美將以 77.59%的市場佔有率主導全球市場，這主要得益於該地區較高的疾病盛行率和強大的公共醫療保健資金投入。

鴉片類藥物使用疾患是一種慢性疾病，其特徵是儘管存在不良後果，仍會強迫性地使用鴉片類藥物。 獲準用於治療的藥物，包括Buprenorphine、Methadone和Naltrexone，均作為受監管的療法獲得許可，用於緩解戒斷症狀、降低復發風險並減少過量用藥死亡率。慢性疾病患者對鴉片類止痛藥的處方量不斷上升，持續增加成癮風險，推動了對長期治療方案的需求。

市場成長驅動因素

鴉片類藥物成癮的上升趨勢仍然是鴉片類藥物使用障礙（OUD）市場的主要成長因素。與癌症、骨科疾病和術後復原相關的慢性疼痛通常需要使用鴉片類鎮痛藥，這增加了長期成癮的風險。全球藥物使用統計資料顯示，鴉片類藥物暴露持續增加，導致 OUD 診斷和治療需求不斷上升。

2021年，美國約有 270萬人受到 OUD 的影響，藥物輔助治療計畫的使用率顯著提高。政府增加對藥物濫用預防和治療計畫的支出，也有助於提高鴉片類藥物使用障礙（OUD）藥物的可及性和償付率。資助計畫擴大了鴉片類藥物治療方案，並增加了門診治療服務，特別是注射長效製劑。

市場限制

OUD 藥物的副作用可能會限制治療順從性和市場成長。常見副作用包括噁心、便秘、呼吸抑制、肌肉疼痛和心理症狀。監管機構對口服Buprenorphine製劑可能引起的牙科併發症發出的警告也影響了患者的信心。安全隱患可能導致治療啟動延遲和長期依從性降低，尤其是在已有疾病的患者中。

此外，與藥物濫用障礙相關的社會污名仍然是及時就醫的障礙，尤其是在發展中地區，這限制了診斷率並降低了治療接受率。

市場趨勢

一個關鍵的市場趨勢是Buprenorphine透皮製劑和長效注射劑的日益普及，這些製劑透過減少每日用藥次數來提高患者的用藥依從性。這些製劑能夠持續釋放藥物並降低復發風險，因此適用於長期門診治療。對緩釋和長效注射劑的投資不斷成長，為需要持續鴉片類藥物成癮管理的患者拓展治療選擇。

數位治療平台和遠距醫療的整合也日益受到關注，它們支持藥物治療的同時進行行為諮詢，並促進患者參與復健計畫。

細分市場分析

依藥物類別

市場細分為Buprenorphine、Methadone和Naltrexone。由於臨床接受度高且擁有多種品牌製劑，Buprenorphine類藥物在2026年佔據了83.24%的市場佔有率，成為市場主導。 SUBLOCADE、SUBOXONE和ZUBSOLV等產品支援長期治療策略，並在已開發市場廣泛應用。

由於仿製藥日益普及以及臨床分發受到監管限制，Methadone的市場佔有率下降。Naltrexone的使用仍然有限，原因在於其製劑種類有限，且醫生將其作為一線治療藥物的意願不高。

依給藥途徑

根據給藥途徑，市場分為口服和注射給藥。腸外給藥領域，由於長效注射劑的廣泛應用（可穩定藥物暴露並降低濫用風險），預計到2026年將佔市場佔有率的84.65%。口服製劑因其便利性和門診治療的靈活性而持續穩定成長。

依通路劃分

通路包括院內藥房、零售藥房和線上藥房。由於注射療法通常透過監督治療方案進行，院內藥房佔據主導地位，預計到2026年將佔 46.19%的市場佔有率。零售藥房在口服藥物的配發方面仍然發揮著重要作用，而線上藥局則因其便利性和隱私性優勢而不斷擴張。

區域展望

北美預計仍將是最大的區域市場，到2025年市場規模將達到30.4億美元，這主要得益於該地區較高的成癮率和完善的治療體系。美國市場預計到2026年將達到30.4億美元，主要得益於強而有力的償付政策和聯邦資助計畫。

歐洲由於Buprenorphine療法的日益普及，因此保持第二的位置。截至2026年，英國市場規模將達9,000萬美元，德國將達到7,000萬美元。亞太地區由於醫療保健支出增加和宣傳活動的開展，呈現出強勁的成長動能。到2026年，中國市場規模將達到1億美元，日本將達到8,000萬美元，印度將達到5,000萬美元。由於診斷率上升和醫療保健投資增加，拉丁美洲和中東及非洲地區的市場持續成長。

報告涵蓋範圍

本報告詳細分析了2025年、2026年和2034年的市場規模和價值，並依藥物類別、給藥途徑和通路進行了細分。本研究涵蓋北美、歐洲、亞太地區和世界其他地區的區域市場評估，並提供了主要經濟體的國別市場價值。本研究檢視了塑造全球鴉片類藥物使用障礙治療格局的產業發展、監管審批、產品上市、合作關係和臨床創新。 Buprenorphine仍將是領先的藥物類別，到2026年將佔據83.24%的市場佔有率，這主要得益於多種品牌製劑的供應以及患者對長效注射劑和透皮製劑日益成長的偏好，這些製劑能夠提高治療依從性並降低復發風險。到2026年，腸外給藥途徑將佔84.65%的市場佔有率，這凸顯了臨床上對在結構化治療環境中進行監督下的長效治療的偏好。同時，醫院藥局預計到2026年將維持46.19%的市場佔有率，這反映了鴉片類藥物治療計畫和住院治療機構在藥物管理方面發揮的核心作用。

依地區劃分，北美地區憑藉較高的診斷率和完善的治療基礎設施繼續引領市場。同時，歐洲的Buprenorphine類藥物產品獲準數量不斷增加，且其應用日益廣泛。亞太地區正崛起為高成長地區，這主要得益於醫療保健支出的成長、成癮治療服務可及性的提高以及中國、日本和印度等國家擴大的公眾意識宣傳活動。拉丁美洲以及中東和非洲地區也正逐步擴張，這得益於各國政府對醫療保健和藥物濫用障礙問題的日益重視。

藥物遞送平台、緩釋製劑和數位治療模式的創新持續推動著競爭格局的發展。 Indivior、Alkermes 和 Orexo 等市場領導者不斷透過研發投入、監管審批和策略聯盟來強化其產品組合。同時，其他製造商則專注於緩釋技術和解決方案，以提高患者的依從性。製劑科學的持續進步，加上有利的政策框架和不斷擴大的治療覆蓋範圍，預計將支持全球醫療和門診領域的長期持續成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 關鍵洞察

  • 產品線分析：主要產品
  • 新產品發布
  • 鴉片類藥物使用疾患統計：主要國家和地區
  • 產業趨勢，包括併購和合作
  • COVID-19 對鴉片類藥物使用障礙（OUD）市場的影響

第5章 全球鴉片類藥物使用障礙鴉片類藥物使用障礙（OUD）市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章 北美和全球鴉片類藥物使用情況鴉片類藥物使用障礙（OUD）市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依國家劃分
    • 美國
    • 加拿大

第7章 歐洲鴉片類藥物使用障礙（OUD）市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依國家和地區劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 北歐國家
    • 其他國家/地區歐洲

第8章 亞太地區鴉片類藥物使用障礙（OUD）市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依國家和地區劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 世界其他地區鴉片類藥物使用障礙（OUD）市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別
    • Buprenorphine
    • Methadone
    • Naltrexone
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 注射
  • 市場分析、洞察與預測：依通路
    • 醫院藥房
    • 零售藥房
    • 線上藥房

第10章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • Indivior PLC
    • Alkermes
    • Orexo US, Inc.
    • Titan Pharmaceuticals Inc.
    • Mallinckrodt
    • BioDelivery Sciences International Inc.
    • Viatris（Mylan N.V.）
    • Hikma Pharmaceuticals
    • Camurus
    • Braeburn Inc.
Product Code: FBI102674

Growth Factors of Opioid Use Disorder (OUD) Market

The global Opioid Use Disorder (OUD) market size was valued at USD 3.92 billion in 2025 and is projected to reach USD 4.26 billion in 2026, further expanding to USD 9.27 billion by 2034. Market expansion is driven by increasing opioid addiction prevalence, rising government intervention programs, and growing availability of medication-assisted treatment options. In 2025, North America dominated the global market with a share of 77.59%, supported by high disease prevalence and strong public healthcare funding.

Opioid Use Disorder is a chronic medical condition characterized by compulsive opioid use despite harmful consequences. Approved medications for treatment include buprenorphine, methadone, and naltrexone, which are regulated therapies authorized for reducing withdrawal symptoms, relapse risk, and overdose mortality. Rising prescription rates for opioid-based pain medications for chronic diseases continue to contribute to dependency risks, thereby increasing the demand for long-term treatment solutions.

Market Growth Factors

The growing incidence of opioid addiction remains a major growth driver for the OUD market. Chronic pain conditions related to cancer, orthopedic disorders, and post-surgical recovery often require opioid-based analgesics, which increase long-term dependency risks. Global drug usage statistics indicate a steady rise in opioid exposure, contributing to higher OUD diagnosis rates and treatment demand.

In the U.S., approximately 2.7 million individuals were affected by OUD in 2021, driving strong utilization of medication-assisted treatment programs. Increased government spending on substance abuse prevention and treatment programs is also supporting drug accessibility and insurance reimbursement for OUD medications. Funding initiatives are expanding opioid treatment programs and increasing availability of clinic-based therapies, especially injectable long-acting formulations.

Market Restraints

Adverse effects associated with OUD medications may restrict treatment adherence and market growth. Common side effects include nausea, constipation, respiratory depression, muscle pain, and psychological symptoms. Regulatory warnings regarding dental complications associated with buprenorphine oral formulations have also impacted patient confidence. Safety concerns may delay therapy initiation or reduce long-term compliance, particularly in patients with pre-existing medical conditions.

In addition, social stigma related to substance abuse disorders remains a barrier to seeking timely medical care, especially in developing regions, limiting diagnosis rates and reducing treatment penetration.

Market Trends

A key trend in the market is the increasing adoption of buprenorphine transdermal and long-acting injectable therapies, which improve compliance by reducing daily dosing requirements. These formulations offer steady drug delivery and lower relapse risks, making them suitable for long-term outpatient management. Growing investments in extended-release formulations and depot injections are expanding therapeutic options for patients requiring continuous opioid dependence control.

Digital therapy platforms and telemedicine integration are also gaining attention, supporting behavioral counseling alongside pharmacological treatment and improving patient engagement in recovery programs.

Segmentation Analysis

By Drug Class

The market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment dominated the market with a share of 83.24% in 2026, driven by high clinical acceptance and multiple branded drug formulations. Products such as SUBLOCADE, SUBOXONE, and ZUBSOLV support long-term treatment strategies and are widely prescribed in developed markets.

Methadone holds a smaller share due to increased generic availability and regulatory restrictions on clinic-based distribution. Naltrexone adoption remains limited due to fewer available formulations and lower physician preference for first-line therapy.

By Route of Administration

Based on route of administration, the market is categorized into oral and parenteral. The parenteral segment accounted for 84.65% market share in 2026, supported by widespread use of injectable depot therapies that ensure consistent drug exposure and reduce misuse risks. Oral formulations continue to grow steadily due to patient convenience and outpatient treatment flexibility.

By Distribution Channel

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated with a 46.19% share in 2026, as injectable therapies are typically administered through supervised treatment programs. Retail pharmacies remain critical for oral medication dispensing, while online pharmacies are expanding due to convenience and privacy benefits.

Regional Outlook

North America remained the largest regional market with USD 3.04 billion in 2025, supported by high addiction prevalence and extensive treatment infrastructure. The U.S. market reached USD 3.04 billion by 2026, driven by strong reimbursement policies and federal funding programs.

Europe ranks second, supported by rising adoption of buprenorphine therapies. By 2026, the U.K. market was valued at USD 0.09 billion, while Germany reached USD 0.07 billion. Asia Pacific shows strong growth momentum, with increasing healthcare spending and awareness campaigns. By 2026, China reached USD 0.10 billion, Japan USD 0.08 billion, and India USD 0.05 billion. Latin America and Middle East & Africa continue to expand due to rising diagnosis rates and healthcare investments.

Competitive Landscape

The market is dominated by Indivior PLC, Alkermes, and Orexo AB, which together hold a significant market share through extensive buprenorphine and naltrexone portfolios. These companies focus on long-acting injectable therapies, improved delivery platforms, and regulatory approvals to expand treatment accessibility.

Other notable players include Titan Pharmaceuticals, Mallinckrodt Pharmaceuticals, Viatris, Hikma Pharmaceuticals, and Camurus, which are investing in extended-release technologies and novel drug delivery systems to improve patient adherence.

Report Coverage

The report provides detailed analysis of market size and value for 2025, 2026, and 2034, along with segmentation by drug class, route of administration, and distribution channel. It includes regional market evaluation across North America, Europe, Asia Pacific, and the rest of the world, with country-level market values for major economies. The study examines industry developments, regulatory approvals, product launches, partnerships, and clinical innovation trends shaping the global opioid use disorder treatment landscape.

Conclusion

The Opioid Use Disorder (OUD) market is positioned for strong expansion from USD 3.92 billion in 2025 to USD 4.26 billion in 2026, reaching USD 9.27 billion by 2034, reflecting the growing global burden of opioid dependency and the rising demand for structured, medication-assisted treatment programs. High disease prevalence, particularly in North America with a 77.59% market share in 2025, continues to shape treatment adoption patterns, supported by strong reimbursement frameworks and large-scale government funding initiatives focused on substance abuse prevention and recovery.

Buprenorphine remains the dominant drug class, accounting for 83.24% market share in 2026, driven by the availability of multiple branded formulations and increasing preference for long-acting injectable and transdermal delivery systems that improve treatment adherence and reduce relapse risks. The dominance of the parenteral route with 84.65% share in 2026 highlights the clinical preference for supervised, long-acting therapies in structured treatment settings, while hospital pharmacies maintaining 46.19% share in 2026 reflects the central role of opioid treatment programs and inpatient care facilities in administering these medications.

Regionally, North America continues to lead due to high diagnosis rates and well-established treatment infrastructure, while Europe benefits from expanding product approvals and strong adoption of buprenorphine-based therapies. Asia Pacific is emerging as a high-growth region due to increasing healthcare expenditure, improving access to addiction treatment services, and rising public awareness initiatives in countries such as China, Japan, and India. Latin America and the Middle East & Africa are also gradually expanding as healthcare access and policy attention toward substance abuse disorders increase.

Competitive dynamics remain driven by innovation in drug delivery platforms, long-acting formulations, and digital treatment support models. Market leaders such as Indivior, Alkermes, and Orexo continue to strengthen their portfolios through R&D investments, regulatory approvals, and strategic collaborations, while other manufacturers focus on extended-release technologies and improved patient compliance solutions. Ongoing advancements in formulation science, coupled with supportive policy frameworks and expanding treatment coverage, are expected to sustain long-term growth across institutional and outpatient treatment settings worldwide.

Segmentation By Drug Class

  • Buprenorphine
  • Methadone
  • Naltrexone

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

By Region

  • North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
    • Japan
    • China
    • India
    • Australia
    • South East Asia
    • Rest of Asia Pacific
  • Rest of the World (By Drug Class, By Route of Administration, By Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, Key Products
  • 4.2. New Product Launches
  • 4.3. Statistics of Opioid Use Disorder by Key Countries/Region
  • 4.4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of COVID-19 on Opioid Use Disorder (OUD) Market

5. Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Buprenorphine
    • 5.1.2. Methadone
    • 5.1.3. Naltrexone
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals Pharmacies
    • 5.3.2. Retail Pharmacies & Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Buprenorphine
    • 6.1.2. Methadone
    • 6.1.3. Naltrexone
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals Pharmacies
    • 6.3.2. Retail Pharmacies & Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Buprenorphine
    • 7.1.2. Methadone
    • 7.1.3. Naltrexone
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals Pharmacies
    • 7.3.2. Retail Pharmacies & Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Buprenorphine
    • 8.1.2. Methadone
    • 8.1.3. Naltrexone
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals Pharmacies
    • 8.3.2. Retail Pharmacies & Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Buprenorphine
    • 9.1.2. Methadone
    • 9.1.3. Naltrexone
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals Pharmacies
    • 9.3.2. Retail Pharmacies & Stores
    • 9.3.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Indivior PLC
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT analysis
      • 10.2.1.4. Recent developments
      • 10.2.1.5. strategies
      • 10.2.1.6. financials (based on availability)
    • 10.2.2. Alkermes
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT analysis
      • 10.2.2.4. Recent developments
      • 10.2.2.5. strategies
      • 10.2.2.6. financials (based on availability)
    • 10.2.3. Orexo US, Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT analysis
      • 10.2.3.4. Recent developments
      • 10.2.3.5. strategies
      • 10.2.3.6. financials (based on availability)
    • 10.2.4. Titan Pharmaceuticals Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT analysis
      • 10.2.4.4. Recent developments
      • 10.2.4.5. strategies
      • 10.2.4.6. financials (based on availability)
    • 10.2.5. Mallinckrodt
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT analysis
      • 10.2.5.4. Recent developments
      • 10.2.5.5. strategies
      • 10.2.5.6. financials (based on availability)
    • 10.2.6. BioDelivery Sciences International Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT analysis
      • 10.2.6.4. Recent developments
      • 10.2.6.5. strategies
      • 10.2.6.6. financials (based on availability)
    • 10.2.7. Viatris (Mylan N.V.)
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT analysis
      • 10.2.7.4. Recent developments
      • 10.2.7.5. strategies
      • 10.2.7.6. financials (based on availability)
    • 10.2.8. Hikma Pharmaceuticals
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT analysis
      • 10.2.8.4. Recent developments
      • 10.2.8.5. strategies
      • 10.2.8.6. financials (based on availability)
    • 10.2.9. Camurus
      • 10.2.9.1. Overview
      • 10.2.9.2. Products
      • 10.2.9.3. SWOT analysis
      • 10.2.9.4. Recent developments
      • 10.2.9.5. strategies
      • 10.2.9.6. financials (based on availability)
    • 10.2.10. Braeburn Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products
      • 10.2.10.3. SWOT analysis
      • 10.2.10.4. Recent developments
      • 10.2.10.5. strategies
      • 10.2.10.6. financials (based on availability)

List of Tables

  • Table 1: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Rest of the World Opioid Use Disorder (OUD) Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Opioid Use Disorder (OUD) Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Opioid Use Disorder (OUD) Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 8: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 10: North America Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 12: North America Opioid Use Disorder (OUD) Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Opioid Use Disorder (OUD) Market Value Share (%), By Country, 2023
  • Figure 14: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 16: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 18: Europe Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 20: Europe Opioid Use Disorder (OUD) Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Opioid Use Disorder (OUD) Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 22: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 24: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 26: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 28: Asia Pacific Opioid Use Disorder (OUD) Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Opioid Use Disorder (OUD) Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 30: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023
  • Figure 32: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023
  • Figure 34: Rest of the World Opioid Use Disorder (OUD) Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023
  • Figure 36: Global Opioid Use Disorder (OUD) Market Share (%), By Company, 2023